Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2013 | 03-2013 | 12-2012 | 09-2012 | 06-2012 | |
| Sales | 10,166,040 | 9,874,552 | 10,781,850 | 10,511,870 | 10,210,000 |
| Cost of Goods | 3,029,380 | 3,070,110 | 3,226,959 | 3,287,770 | 3,154,530 |
| Gross Profit | 7,137,180 | 6,983,880 | 7,692,141 | 7,024,230 | 7,078,690 |
| Operating Expenses | 4,977,660 | 4,636,340 | 3,989,579 | 4,372,340 | 4,434,600 |
| Operating Income | 2,159,380 | 2,168,211 | 3,566,271 | 2,852,530 | 2,621,400 |
| Interest Expense | 302,630 | 0 | 1,280,760 | 0 | 0 |
| Other Income | 121,870 | 24,059 | 526,689 | -466,890 | -163,660 |
| Pre-tax Income | 1,978,620 | 2,192,270 | 2,812,200 | 2,385,640 | 2,457,740 |
| Income Tax | 313,380 | 593,510 | 1,454,510 | 496,080 | 368,970 |
| Net Income Continuous | 1,605,245 | 1,466,457 | 1,369,526 | 1,807,005 | 1,981,000 |
| Net Income | $1,605,245 | $1,466,457 | $1,369,526 | $1,807,005 | $1,981,000 |
| EPS Basic Total Ops | 0.83 | 0.76 | 0.71 | 0.93 | 1.00 |
| EPS Basic Continuous Ops | 0.83 | 0.76 | 0.71 | 0.92 | 1.00 |
| EPS Diluted Total Ops | 0.81 | 0.76 | 0.71 | 0.91 | 0.99 |
| EPS Diluted Continuous Ops | 0.81 | 0.76 | 0.71 | 0.91 | 0.99 |
| EBITDA(a) | $2,988,370 | $3,036,721 | $4,093,281 | $3,274,140 | $3,015,570 |